FDA Approves New Formulation of Helsinn’s Nausea Treatment Akynzeo

The FDA has approved a liquid formulation of Helsinn’s nausea treatment Akynzeo (fosnetupitant/palonosetron) injection.

The ready-to-dilute solution does not have to be refrigerated during distribution or storage, and it reduces the preparation time for intravenous administration. It can also be stored for up to 24 hours at room temperature without dilution.

Akynzeo is approved for prevention of chemotherapy-induced nausea and vomiting.